Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19321469 | 0.92 | CYP1A2 (0.74) | CYP1A2MAPTPOLBCYP3A4CYP2C9 | |
| SCHEMBL9781436 | 0.83 | FASN (0.50) | CYP1A2POLBCYP3A4CYP2C9TSHR | |
| SCHEMBL9225121 | 0.82 | ALDH1A1 (0.60) | CYP1A2CYP2C9KDM4EALDH1A1HPGD | |
| SCHEMBL8784597 | 0.82 | CYP1A2 (0.74) | CYP1A2POLBCYP3A4CYP2C9TSHR | |
| SCHEMBL7825662 | 0.82 | PADI4 (0.57) | MAPTPOLBTSHRKDM4EALDH1A1 | |
| SCHEMBL8783422 | 0.81 | KDM4E (0.77) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL12686482 | 0.81 | FASN (0.57) | CYP1A2POLBCYP3A4CYP2C9TSHR | |
| SCHEMBL10614041 | 0.81 | CYP1A2 (0.54) | CYP1A2MAPTPOLBCYP3A4CYP2C9 | |
| SCHEMBL7255932 | 0.80 | KDM4E (0.47) | CYP1A2MAPTPOLBCYP3A4CYP2C9 | |
| SCHEMBL19326061 | 0.80 | CYP1A2 (0.74) | CYP1A2MAPTPOLBCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405303-B2 | Substituted quinoline compounds for use as selective estrogen receptor modulator | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070203180-A1 | e.g. 4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyl)oxyphenyl]-2-propenoic acid; bone diseases, aging, osteoporosis, osteoarthritis, atherosclerosis, menopausal disorders,liver and cardiovascular disorder, breast cancer | SMITHKLINE BEECHAM CORPORATION | 2007-08-30 | — | — | US | disclosed |
| EP-1727802-A1 | SUBSTITUTED QUINOLINE COMPOUNDS FOR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005082857-A1 | SUBSTITUTED QUINOLINE COMPOUNDS FOR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATOR | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203180-A1 | e.g. 4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyl)oxyphenyl]-2-propenoic acid; bone diseases, aging, osteoporosis, osteoarthritis, atherosclerosis, menopausal disorders,liver and cardiovascular disorder, breast cancer | GPER1, ESRRG, ESR2 | CYP1A2 193/4885MAPT 4752/4885POLB 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.